| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 14 | 10 | 16 | NaN |
| Cost of revenue | 42 | 42 | 41 | NaN |
| Payroll related expenses | 4,598 | 4,493 | 4,360 | NaN |
| Consulting and professional fees | 1,923 | 1,555 | 1,514 | NaN |
| Stock-based compensation expense | 835 | 1,019 | 1,254 | NaN |
| Equipment, lab supplies, and facility expenses | 313 | 302 | 422 | NaN |
| Clinical studies and outside processing | 122 | 468 | 394 | NaN |
| Depreciation and amortization | 164 | 215 | 214 | NaN |
| Other segment items | 1,377 | 870 | 797 | NaN |
| Loss from operations | -9,360 | -8,954 | -8,980 | NaN |
| Interest expense | 2 | 1 | 2 | NaN |
| Other income, net | 963 | 1,074 | 1,168 | NaN |
| Net loss | -8,399 | -7,881 | -7,814 | -16,233 |
| Depreciation and amortization | 193 | 244 | 243 | 453 |
| Stock-based compensation | 835 | 1,019 | 1,254 | 2,837 |
| Non-cash lease expense | 67 | 66 | 125 | 301 |
| Non-cash investment income, net | -6 | -242 | -33 | -39 |
| Other | 16 | 0 | 0 | 5 |
| Accounts receivable | -1 | -2 | -3 | -17 |
| Other receivables | NaN | 0 | 0 | -19 |
| Prepaid expenses and other assets | 1,270 | 467 | 488 | -603 |
| Accounts payable | -70 | -94 | 52 | -967 |
| Accrued and other current liabilities | -116 | 753 | 16 | -87 |
| Deferred revenue | -5 | -4 | 99 | -3 |
| Purchase of intangible assets | NaN | 0 | 0 | 0 |
| Net cash used in operating activities | -8,774 | -6,120 | -6,477 | -13,026 |
| Purchases of marketable securities | 1,007 | 7,780 | 7,969 | 71,863 |
| Proceeds from maturities and sales of marketable securities | 10,000 | 14,000 | 13,250 | 32,586 |
| Purchases of property and equipment | 8 | 330 | 112 | 284 |
| Proceeds from employee stock purchase plan | NaN | 28 | 0 | 75 |
| Net cash provided by (used in) investing activities | 8,985 | 5,890 | 5,169 | -39,561 |
| Proceeds from public offering of common stock, net of issuance costs | 0 | 0 | 0 | 53,610 |
| Proceeds from exercise of stock options | 22 | 66 | 393 | 48 |
| Finance lease principal payments | 2 | 1 | 20 | 173 |
| Net cash provided by financing activities | 20 | 93 | 373 | 53,560 |
| Net increase in cash and cash equivalents | 231 | -137 | -935 | 973 |
| Cash and cash equivalents at beginning of period | 3,944 | 4,081 | 4,043 | NaN |
| Cash and cash equivalents at end of period | 4,175 | 3,944 | 4,081 | NaN |
SERA PROGNOSTICS, INC. (SERA)
SERA PROGNOSTICS, INC. (SERA)